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Abstract
Background: Eighty percent of all breast cancers and almost 90% of breast cancer deaths occur among
post-menopausal women. We used a nested case control design to examine the association between
nonsteroidal anti-inflammatory drug (NSAID) use and breast cancer occurrence among women over 65
years of age. The cyclooxygenase (COX)-2 enzyme is expressed more in breast cancers than in normal
breast tissue. COX-2 inhibition may have a role in breast cancer prevention.
Methods: In the Canadian province of Quebec, physician services are covered through a governmental
insurance plan. Medication costs are covered for those ≥ 65 years of age and a publicly funded screening
program for breast cancer targets all women 50 years of age or older. We obtained encrypted data from
these insurance databases on all women ≥ 65 years of age who filled a prescription for COX-2 inhibitors,
non-selective NSAIDs (ns-NSAIDs), aspirin, or acetaminophen between January 1998 and December
2002. Cases were defined as those women who have undergone mammography between April 2001 and
June 2002 and had a diagnosis of breast cancer within six months following mammography. Controls
included those who have undergone mammography between April 2001 and June 2002 without a diagnosis
of any cancer during the six months following mammography. The exposure of interest, frequent NSAID
use, was defined as use of ns-NSAIDs and/or COX-2 inhibitors for ≥ 90 days during the year prior to
mammography. Frequent use served as a convenient proxy for long term chronic use.
Results: We identified 1,090 cases and 44,990 controls. Cases were older and more likely to have breast
cancer risk factors. Logistic regression models adjusting for potential confounders showed that frequent
use of ns-NSAIDs and/or COX-2 inhibitors was associated with a lower risk of breast cancer (OR: 0.75,
95% confidence interval 0.64–0.89). Results were similar for COX-2 inhibitors (0.81, 0.68–0.97) and ns-
NSAIDs (0.65, 0.43–0.99), when assessed separately. Frequent use of aspirin at doses > 100 mg/day in the
year prior to mammography was also associated with a lower risk of breast cancer (0.75, 0.64–0.89).
However, use of aspirin at doses ≤ 100 mg/day did not have any association with breast cancer (0.91, 0.71–
1.16).
Conclusion: Women who use NSAIDs or doses of aspirin > 100 mg frequently may have a lower risk of
breast cancer.
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Background
Breast cancer is the most frequently diagnosed cancer and
the second leading cause of cancer death in Canadian
women[1]. Eighty percent of all breast cancers and almost
90% of breast cancer deaths occur among women 50 years
of age or older [1]. Mammographic screening is an effec-
tive means of early breast cancer detection among women
in this age group[2]. Studies have shown that aspirin and
non-aspirin nonselective nonsteroidal anti-inflammatory
drugs (ns-NSAIDs) may have a role in the prevention of
breast cancer in the general population. [3-8] Ns-NSAIDs
and the cyclo-oxygenase (COX)-2 inhibitors inhibit the
COX-2 enzyme that is expressed more in breast cancers
than in normal breast tissue[9][10] In vitro and animal
studies have shown that the inhibition of COX-2 may pre-
vent tumor formation and growth [11-15].
The well known serious gastrointestinal (GI) toxicity of
ns-NSAIDs, thought to be due to the inhibition of the con-
stitutive form of COX, the COX-1 enzyme, has prevented
their use for chemoprevention. The COX-2 inhibitors
have less GI toxicity compared to ns-NSAIDs [16,17].
These agents appeared to be an attractive option for cancer
chemoprevention until recently when concerns about
their cardiovascular (CV) safety were raised. In fact, in
2004, two cancer prevention trials [18-20] were termi-
nated prematurely because patients randomized to the
COX-2 inhibitor arms experienced more CV events com-
pared to patients given placebo.
Continuous use of ns-NSAIDs or COX-2 inhibitors for
cancer chemoprevention in healthy individuals appears
problematic. However, patients who suffer from arthritis
have few other options to control their pain and inflam-
mation. Acetaminophen alone at regular doses may be
inadequate for these patients and high doses are associ-
ated with hepatotoxicity[21].
We sought to determine whether frequent use of NSAID
or aspirin reduces the risk for breast cancer. Although ns-
NSAIDs and aspirin may be associated with GI toxicity
and COX-2 inhibitors may increase CV risk, among
patients who require NSAIDs for pain control or aspirin
for cardioprotection, breast cancer risk reduction may be
an incidental benefit.
Methods
Data source
The Québec provincial government health insurance
agency, the Régie de l'Assurance Maladie du Québec
(RAMQ), covers all in-patient and out-patient medical
services for the entire population of the Canadian prov-
ince of Québec including a screening program for breast
cancer offered to all women 50 years of age or over. The
RAMQ also covers the costs of outpatient prescription
drugs for all individuals aged 65 years and older residing
in Quebec. RAMQ has provided unrestricted coverage for
ns-NSAIDs, aspirin and acetaminophen for at least the last
two decades, celecoxib since October 1999, and rofecoxib
since April 2000 until its withdrawal in September 2004.
Ibuprofen, aspirin and acetaminophen are also available
over-the-counter. The data in the drug claims database
have been validated for accuracy of prescription
claims[22] and have been used in other studies [23-25].
Source population
From the RAMQ database, we obtained in- and out-
patient physician and procedure claims, prescription drug
claims, and demographic data on all patients aged 65
years and older who were dispensed COX-2 inhibitors, ns-
NSAIDs, aspirin, or acetaminophen between January
1998 and December 2002 in the province. Patients
retained from this population were 1) female, 2) ≥ 66
years of age and therefore had been covered by the drug
plan for at least one year, and 3) had undergone bilateral
mammography between April 2001 and June 2002. The
date of the bilateral mammography was defined as the
index date. Women who, in the three years prior to the
index date, had a diagnosis of any type of cancer, or a mas-
tectomy were excluded. Under the assumption that
women undergoing mammography for screening pur-
poses require these tests at no more than yearly intervals,
we excluded patients who underwent a mammogram in
the year prior to the index date. RAMQ uses the same diag-
nostic codes as those given by the International Classifica-
tion of Diseases, 9th review (ICD-9). RAMQ procedural
codes are available upon request.
Study design and selection of cases and controls
We conducted a nested case-control study. From the
source population defined above, we identified cases and
controls. The cases were those women who underwent a
diagnostic or therapeutic test or procedure of the breast
(fine needle aspirate, puncture, core or excision biopsy,
capsulectomy or mastectomy), and who were given a
diagnosis of breast cancer (ICD codes 174.0 to 174.9 and
233.0) during the six months following the index date.
The controls were those patients who were not diagnosed
with breast cancer or any other type of cancer in the six
months following the index date.
Exposure
We considered regular use of pain suppressing medica-
tions in the year prior to the index date as an indicator of
chronic use of these medications in preceding years.
Patients who filled a prescription for any ns-NSAID, COX-
2 inhibitor, aspirin or acetaminophen in the year prior to
the index date were identified. The number of days sup-
plied for each study drug during that year was recorded.BMC Cancer 2005, 5:159 http://www.biomedcentral.com/1471-2407/5/159
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The primary exposure was the filling of one or more pre-
scriptions for celecoxib and/or rofecoxib and/or any ns-
NSAID for a total of ≥ 90 days in the year prior to the
index date. We also identified patients who were exposed
to ≥ 90 days of aspirin and patients exposed to ≥ 90 days
of acetaminophen in the year prior to the index date. Sub-
groups of exposure were defined for those exposed to ≥ 90
days of ns-NSAIDs, both COX-2 inhibitors, and rofecoxib
and celecoxib, separately. We also separated exposure to ≥
90 days of aspirin into two groups according to the mean
daily dose prescribed, whether ≤ 100 mg or >100 mg.
Non-exposed patients were those who did not receive any
prescription for a COX-2 inhibitor, ns-NSAID, aspirin or
acetaminophen in the year prior to the index date.
Patient characteristics at the index date
The baseline patient characteristics available from the
RAMQ database were determined based on demographic
data, prescription claims, and in- and out-patient physi-
cian and procedure claims. They were: 1) age, defined cat-
egorically as 66–74, 75–84 and ≥ 85 years old; 2) a history
of diagnostic and therapeutic breast tests and procedures,
namely fine needle aspirate, puncture, core or excision
biopsy or capsulectomy, in the three years prior to the
index date; 3) a diagnosis of benign neoplasm of the
breast (ICD code 217) in the three years prior to the index
date; 4) mammography in years 2 or 3 prior to the index
date; 5) a diagnosis of another breast disease in the three
years prior to the index date (ICD codes 238.3, 239.3,
793.8 and 610.0 to 611.9); 6) estrogen replacement ther-
apy in the year prior to the index date; 7) combined estro-
gen and progesterone replacement therapy in the year
prior to the index date; and 8) visit to a gynecologist in the
year prior to the index date.
Statistical analysis
The baseline patient characteristics of the cases and con-
trols were compared using descriptive statistics.
Primary analysis
Logistic regression models were used to determine the
association between exposure to ≥ 90 days of ns-NSAIDs
Table 1: Patient characteristics at the index date and mortality in the following 6 months
Cases (%) Controls (%)
Number of patients 1,090 44,990
Mean age at index date ± SD 74.1 ± 5.7 71.1 ± 4.3
Number of patients 66–74 670 (61.5) 36,900 (82.0)
Number of patients 75–84 369 (33.9) 7,665 (17.0)
Number of patients ≥ 85 51 (0.05) 425 (0.9)
Risk factors
Mammography in years 2 or 3 prior to the 
index date
514 (47.2) 35,229 (78.3)
History of diagnostic and therapeutic breast 
procedures in the 3 prior to the index date
19 (1.7) 296 (0.7)
Benign neoplasm of the breast in the 3 years 
prior to the index date
15 (1.4) 319 (0.7)
Other breast disease in the 3 years prior to 
the index date
169 (15.5) 4,667 (10.4)
Estrogen replacement therapy in the year 
prior to the index date
299 (27.4) 17,837 (39.7)
Combined estrogen/progesterone therapy 
in the year prior to the index date
101 (9.3) 4,943 (11.0)
Visit to a gynecologist in the year prior to the 
index date
152 (13.9) 10,076 (22.4)
Exposure to the drugs of interest (one or more 
prescriptions in the year prior to the index 
date)
Ns-NSAID/COX-2 inhibitors 443 (40.6) 22,126 (49.2)
Ns-NSAIDs 102 (9.4) 5,572 (12.4)
COX-2 inhibitors 388 (35.8) 19,228 (42.7)
Rofecoxib 242 (22.2) 11,498 (25.6)
Celecoxib 203 (18.6) 10,269 (22.8)
Aspirin 329 (30.2) 13,391 (29.8)
Acetaminophen 253 (23.2) 10,159 (22.6)
Not exposed* 375 (34.4) 12,260 (27.3)
SD – standard deviation
*Not exposed refers to the group of patients who were not exposed to ns-NSAIDs, aspirin, COX-2 inhibitors or acetaminophen during the year 
prior to the index dateBMC Cancer 2005, 5:159 http://www.biomedcentral.com/1471-2407/5/159
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and/or COX-2 inhibitors, aspirin at doses ≤ 100 mg/day,
aspirin at doses >100 mg/day and acetaminophen and
breast cancer, using the non-exposed patients as the refer-
ence group. The models were adjusted for patient charac-
teristics at the index date, as defined above. We adjusted
for whether patients had at least one visit to a gynecologist
in the year prior to the index date and whether they had
mammography in the years 2–3 prior to the index date to
reduce a possible surveillance bias.
Secondary analysis
We conducted an analysis identical to the primary analy-
sis including only patients who also underwent mam-
mography in the years 2–3 prior to the index date. This
limited the analysis to those women who were adherent
to the screening program. We also examined the effect of
exposure to at least 90 days of ns-NSAIDs and/or COX-2
inhibitors excluding the prescriptions filled in the month
prior to index date. This analysis would exclude prescrip-
tions that could have been prescribed for symptoms
related to the referral of the patient to mammography.
Sample size calculation
We calculated that 558 cases and 5578 controls (a total
sample size of 6136) were needed for a two-group conti-
nuity corrected chi-square test with a 0.05 two-sided sig-
nificance level to have 80% power to detect an odds ratio
of 0.72 between the cases and the controls, assuming that
15% of cases would be exposed. This sample size calcula-
tion was based on a ratio of 10 controls to 1 case. How-
ever, since matching on all or some of the patient
characteristics may introduce biases and, more impor-
tantly, since there were no costs associated to the selection
of controls, we decided to use all eligible controls for the
analysis.
All analyses were performed using the statistical software
SAS version 8.2 (SAS Institute Inc., Cary, North Carolina).
We performed our sample size calculation using
nQuery20.
Results
Study population
Among 418,458 women in our dataset, 68,641 were at
least 66 years of age and had undergone bilateral mam-
mography between April 2001 and June 2002. Of these
patients, 46,080 fulfilled eligibility criteria, including
1,090 (2.4%) cases and 44,990 (97.6%) controls. Patient
characteristics are presented in Table 1. Patients diagnosed
with breast cancer were slightly older than controls. Com-
pared to controls, cases more commonly had a history of
diagnostic and therapeutic breast procedures and a history
of benign neoplasm of the breast or other breast diseases
in the three years prior to the index date. Cases used estro-
gen replacement therapy less frequently than controls and
were less likely than controls to have seen a gynecologist
in the year prior to the index date. Twenty one cases
(1.9%) and 101 controls (0.2%) died during the 6-month
period following the index date.
Exposure to the drugs of interest
Frequency of exposure to the medications of interest are
indicated in Table 2 (≥ 90 days of ns-NSAIDs/COX-2
inhibitors, aspirin, acetaminophen). Controls were more
Table 2: Exposures to ≥ 90 days of COX-2 inhibitors, ns-NSAIDs, aspirin and acetaminophen in the year prior to the index date: Crude 
and adjusted odds ratios.
Exposure to ≥ 90 days Cases N of patients (%) Controls N of patients (%) Crude odds ratios Adjusted odds ratios*
Ns-NSAID/COX-2 
inhibitors
186 (17.1) 8,681 (19.3) 0.70 (0.59, 0.84) 0.75 (0.64, 0.89)
COX-2 inhibitors 166 (15.2) 7,412 (16.5) 0.73 (0.61, 0.88) 0.81 (0.68, 0.97)
Rofecoxib 76 (7.0) 3,597 (8.0) 0.69 (0.54, 0.89) 0.80 (0.63, 1.02)
Celecoxib 93 (8.5) 3,792 (8.4) 0.80 (0.64, 1.00) 0.88 (0.70, 1.10)
Ns-NSAIDs 24 (2.2) 1,278 (2.8) 0.61 (0.40, 0.93) 0.65 (0.43, 0.99)
Aspirin
average daily dose ≤ 100 
mg/day
78 (7.2) 2,894 (6.4) 0.88 (0.69, 1.13) 0.91 (0.71, 1.16)
average daily dose >100 
mg/day#
211 (19.4) 8,419 (18.7) 0.82 (0.69, 0.97) 0.75 (0.64, 0.89)
Acetaminophen 74 (6.8) 2,534 (5.6) 0.95 (0.74, 1.23) 0.91 (0.71, 1.16)
Not exposed § 375 (34.4) 12,260 (27.3) 1 (Reference) 1(Reference)
* Adjusted for age, mammography in years 2 or 3 prior to index date, breast procedure in the prior 3 years, benign neoplasm of the breast in the 
prior 3 years, other breast disease in the prior 3 years, estrogen replacement therapy in the prior year, and visit to a gynecologist in the prior year- 
these variables were risk factors for breast cancer but their inclusion in the model did not alter substantially the effect of exposure to the drugs of 
interest.
#90% of all aspirin prescriptions were for ≤ 325 mg/day
§Not exposed refers to the group of patients who were not exposed to ns-NSAIDs, aspirin, COX-2 inhibitors or acetaminophen during the year 
prior to the index dateBMC Cancer 2005, 5:159 http://www.biomedcentral.com/1471-2407/5/159
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likely than cases to be exposed to ≥ 90 days of ns-NSAIDs
and to COX-2 inhibitors. Patients exposed to at least 90
days of either ns-NSAIDs or COX-2 inhibitors during the
year prior to the index date filled on average (± standard
deviation) 8.0 ± 4.4 prescriptions for these drugs during
that year with a median number of 7 prescriptions. Ninety
percent of all aspirin prescriptions were for 325 mg/day or
less and 25% of them were for ≤ 80 mg/day, the median
dose (interquartile range) for all aspirin prescriptions
were 312.5 (80, 312.5).
Patient characteristics associated with breast cancer
Logistic regression models showed that cases were older
(odds ratio, 95% confidence interval for 75–84 years and
≥ 85 years compared to 66–74 years: 1.90, 1.66–2.18 and
3.68, 2.69–5.04, respectively) and more likely to have
received combined estrogen therapy 1.35 (1.06, 1.70) in
the year prior to the index date. Cases were also more
likely to have a history of diagnostic/therapeutic breast
procedures in the three years prior to the index date (2.60,
1.59–4.26), benign breast neoplasm diagnosed in the year
prior to the index date (1.40, 1.12–1.75), and/or other
breast disease in the three years prior to the index date
(1.87, 1.57–2.23). Cases were less likely to have used
estrogen replacement therapy in the year prior to the
index date (0.71, 0.61–0.84). Cases were also less likely to
have seen a gynecologist in the year prior to the index date
(0.68, 0.57–0.81) and to have had mammography in the
years 2–3 prior to the index date (0.29, 0.26–0.33) (data
not shown).
Table 2 shows the crude and adjusted odds ratios of the
association between exposure to the drugs of interest and
breast cancer. Small differences between the crude and
adjusted odds ratios were observed. We investigated these
differences and found that they resulted from the adjust-
ment for other exposure categories. In fact, exposure cate-
gories were not mutually exclusive. For example, some
patients exposed to at least 90 days of ns-NSAIDs and/or
COX-2 inhibitors were also exposed to at least 90 days of
aspirin. When only exposure categories were entered in
the model, the effect of each was adjusted for the effects of
the others. None of the other patient characteristics listed
above was a confounder or effect modifier for exposure to
ns-NSAIDs and/or COX-2 inhibitor. However, age was a
confounder for exposure to aspirin.
As shown in Table 2, exposure to at least 90 days of an ns-
NSAID and/or COX-2 inhibitor (0.75, 0.64–0.89) was
inversely associated with the risk of breast cancer as was
exposure to at least 90 days of aspirin at an average daily
dose > 100 mg (0.75, 0.64 – 0.89). In contrast, exposure
to at least 90 days of aspirin at an average daily dose ≤ 100
mg and exposure to at least 90 days of acetaminophen
were not found to be associated with breast cancer. Expo-
sures to at least 90 days of COX-2 inhibitors (0.81, 0.68–
0.97) or ns-NSAIDs (0.65, 0.43–0.99), assessed sepa-
rately, were associated with a lower risk of breast cancer.
Exposure to at least 90 days of celecoxib (0.88, 0.70–1.10)
or rofecoxib (0.80, 0.63–1.02) showed trends toward an
association with a lower risk of breast cancer.
Secondary analyses
Consistent with the results of the primary analysis, expo-
sure to ≥ 90 days of ns-NSAIDs and/or COX-2 inhibitors
was also associated with a lower risk of breast cancer in a
subgroup analysis of patients who had mammography in
years 2–3 prior to the index date (0.73, 0.55–0.93). Again,
in this subgroup, exposure to ≥ 90 days of acetaminophen
(0.86, 0.59–1.31) and exposure to ≥ 90 days of aspirin at
an average daily dose ≤ 100 mg (0.97, 0.68–1.39) were
not associated with breast cancer. In contrast with the
findings of the primary analysis, exposure to ≥ 90 days of
aspirin at an average daily dose >100 mg (0.93, 0.72–
1.18) did not seem to be associated with breast cancer in
this subgroup. It is difficult to conclude if this difference
was due to chance given the multiple modeling conducted
in this study or to differences in the characteristics of the
women in the two analyses. In particular, in the primary
analysis, only 25% (54/211) of the cases who received
aspirin for 90 days or more at an average daily dose >100
mg also received hormone replacement therapy compared
to 42% (45/93) of women in the secondary analysis.
Thus, there may have been better surveillance of the
women in the secondary analysis. Of note, the effect of
aspirin at an average daily dose >100 mg in the subgroup
analysis differed between women who were not receiving
hormone replacement therapy (0.83, 0.60, 1.15) and
those who did (1.08, 0.74, 1.56).
The results of the main analysis did not change substan-
tially when we reassessed the effect of exposure to ≥ 90
days of ns-NSAIDs and/or COX-2 inhibitors (0.75, 0.63–
0.89), aspirin at an average daily dose ≤ 100 mg (0.90,
0.71, 1.15) aspirin at an average daily dose > 100 mg
(0.75, 0.63, 0.89) and acetaminophen (0.89, 0.69, 1.15)
excluding the prescriptions filled in the month prior to
the index date.
Discussion
In this population-based study of women 65 years of age
or older, we found that patients taking ns-NSAIDs and/or
COX-2 inhibitors and patients taking aspirin at doses
>100 mg/day for a period of ≥ 90 days were at a lower risk
of breast cancer compared to those not taking these med-
ications. Given the cardiovascular risk associated with use
of some COX-2 inhibitors and ns-NSAIDs, regular use of
these agents for primary cancer chemoprevention cannot
be recommended. However, for women who require
these agents for pain control, a concurrent benefit of suchBMC Cancer 2005, 5:159 http://www.biomedcentral.com/1471-2407/5/159
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treatment may be reduced risk of breast cancer. Aspirin is
used most commonly for the prevention of myocardial
infarction and stroke. Although aspirin doses of as little as
80 mg per day are effective for the prevention of cardio-
vascular events, our results suggest that higher doses may
additionally protect women from developing breast can-
cer.
Ns-NSAIDs are COX-1 and COX-2 inhibitors. A signifi-
cant inverse association has been observed in most obser-
vational studies between the use of ns-NSAIDs and the
risk of breast cancer. In a meta-analysis of six cohort and
8 case-control studies, the authors found a significant
18% reduction in breast cancer risk among patients taking
ns-NSAIDs compared to those not taking them. However,
the data were insufficient to estimate a dose-response
effect for duration and frequency of use of any particular
type of ns-NSAID [3]. A subsequent case-control study
found a 24% reduction in breast cancer risk with the reg-
ular use of any ns-NSAID for > 2 months and a stronger
association in prolonged users compared to non-users
(relative risk reduction of 32%) in those having used ns-
NSAIDs for > 9 years compared to non-users[4]. A protec-
tive effect of ns-NSAIDs was recently confirmed in the
Women's Health Initiative (WHI) where regular ns-
NSAID use, defined as two or more tablets per week for 10
or more years, produced a 28% reduction in the risk of
breast cancer[5]. A protective effect of ns-NSAIDs was also
found in a case-control study where occasional as well as
regular use of either prescription or non-prescription ns-
NSAIDs were found to be inversely associated with inva-
sive breast cancer as well as with carcinoma in situ of the
breast [6]. More recently, a case control study found that
long term regular use of ns-NSAIDs was associated with a
decreased risk of breast cancer [7]. There is now growing
evidence that the selective COX-2 inhibitor celecoxib pro-
tects against the development of breast cancer. Treatment
with celecoxib has been shown to significantly reduce the
risk of developing breast cancer in animal models[15],
including a mouse model for HER-2/neu-induced breast
cancer[26], in a dose-dependent fashion[27]. There have
been no clinical studies published to date confirming
these results in humans.
Aspirin
Aspirin is also an irreversible COX enzyme inhibitor[10].
The literature is unclear as to whether aspirin protects
against breast cancer, with some studies suggesting that it
does and others suggesting that it does not[3,28]. We
observed a protective effect on breast cancer of aspirin pre-
scribed at an average dose >100 mg/day but lower doses
of aspirin (≤ 100 mg/day) did not seem to have an effect.
Whereas ns-NSAIDs are usually used in anti-inflamma-
tory doses, aspirin is often used in low, anti-platelet doses
(≤ 325 mg)[29]. However, the dose of aspirin necessary to
have an anti-inflammatory effect is up to 100 times greater
than the anti-platelet dose[10]. In fact, results from the
Women's Health Initiative suggest that the regular use of
low dose aspirin, defined as ≤ 100 mg per day, had no
relationship with the incidence of breast cancer[28]. Sim-
ilarly, an analysis of women in the Cancer Prevention
Study II Nutrition cohort did not find any association
between use of ns-NSAID or aspirin and breast cancer
[30]. In contrast, a case-control study using hospital con-
trols reported an inverse association between both regular
and occasional use of aspirin and breast cancer [8].
Another case-control study using the General Practice
Research database also showed a reduced risk of breast
cancer associated with aspirin and acetaminophen use
[31]. A third case-control study showed a reduction in risk
of breast cancer with aspirin use among women with hor-
mone receptor-positive tumors but not among women
with hormone receptor-negative tumors [32]. Finally, a
study using a cohort of postmenopausal women also
showed a reduction in the risk of breast cancer associated
with frequent aspirin use [33].
We cannot exclude the possibility, however, that the
apparent protective effect of aspirin observed in our study
was a result of surveillance bias among aspirin users.
Women prescribed aspirin for prevention of cardiovascu-
lar disease may be more likely to consistently undergo
preventive interventions such as mammography. Aspirin
users may have therefore been more likely to have under-
gone regular mammographic screening prior to the age of
65 years. Those with a previous history of breast cancer so
detected would have been excluded from our cohort. Con-
sistent with this possibility, we found that the protective
effect of aspirin prescribed at an average dose >100 mg/
day did not persist when we restricted the analysis to
women who have undergone mammography in years 2–
3 prior to the index mammogram.
Limitations
In this study, prescription data were available starting in
1998. However, we used only one year of data to assess
frequent use of the study drugs because in Quebec,
patients are covered by the provincial drug plan starting at
their 65th birthday. Therefore, to have one full year of pre-
scription data available at index date, women had to be 66
years of age or older at that date. To correctly examine
exposure to the drugs of interest in the past 3 years, for
example, women would have had to be at least 68 years of
age at the index date. In designing the study, we thus had
to trade-off the number of patients with the duration of
exposure studied.
Patients may have used over-the-counter aspirin or ibu-
profen (in contrast, rofecoxib, celecoxib and the other ns-
NSAIDs are not available over-the counter in Québec). ABMC Cancer 2005, 5:159 http://www.biomedcentral.com/1471-2407/5/159
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survey conducted by Santé Québec, a provincial public
health agency, showed that in 1998, 17.0% and 2.2% of
the elderly who consumed ns-NSAIDs or aspirin, respec-
tively, acquired them over-the-counter[23]. Québec has
maintained the same drug insurance policy since 1997.
The high number of patients who acquired ns-NSAIDs
over-the-counter suggests that some patients may have
been misclassified according to exposure status and dura-
tion of use. Therefore, some patients in the non-exposed
group could have been exposed to ns-NSAIDs or aspirin
which may have biased the results towards the null and
could have made it more difficult to find an association.
Thus, our estimate of the protective effect of ns-NSAIDs
may be an underestimate.
A number of variables associated with breast cancer risk
are not available in the RAMQ database, including family
history of breast or other cancers, carriage of certain genes
and gynecologic and obstetric history. However, these var-
iables are not likely to be associated with exposure to ns-
NSAIDs or COX-2 inhibitors and thus are unlikely to have
confounded the results. Obesity, however, is a risk factor
for breast cancer in post-menopausal women[34] as well
as for osteoarthritis[35]. As such, it may be associated with
both the exposure, namely ns-NSAIDs and/or COX-2
inhibitors, and the outcome and could be a potential con-
founder. However, if we postulate that cases were more
likely to be obese and therefore more likely have osteoar-
thritis, then they would have used more ns-NSAIDs or
COX-2 inhibitors than controls and this would have
biased our results towards the null. Thus, again, our
results would then underestimate the magnitude of the
true association.
We are aware that the main exposure of at least 90 days of
ns-NSAIDs and/or COX-2 inhibitors may seem to be a rel-
atively short period of time to attribute a protective effect
to a drug on a malignancy that may evolve over many
years. However, existing literature also suggests that rela-
tively short durations of exposures to cyclooxygenase
inhibitors may protect against the progression of tumors.
Recent randomized trials in the field of colorectal adeno-
mas have shown that exposure to aspirin significantly
reduced the number and histological grade of recurrent
adenomas[36,37]. This difference is seen as early as three
to six months after randomization[36].
Moreover, we believe that a minimum of 90 days of expo-
sure is a marker for chronic exposure to ns-NSAIDs in the
past. In fact, among women for whom 3 years of data were
available prior to their index date and who used ns-
NSAIDs and/or COX-2 inhibitors for at least 90 days in
the year prior to the index date, 91% had also used them
in years 2–3 prior.
Conclusion
The ideal agents for chemoprevention and chemotherapy
are those that are effective but that have few side effects.
Although both ns-NSAIDs and COX-2 inhibitors seem to
have similar protective effects on breast cancer, a continu-
ous use of ns-NSAIDs or COX-2 inhibitors for cancer che-
moprevention in healthy individuals appears
problematic. However, in those women who have arthri-
tis and are in need of frequent use of analgesics, ns-NSAID
or COX-2 inhibitor use may offer protection against breast
cancer compared with acetaminophen. Although we can-
not exclude the possibility of surveillance bias among
aspirin users, our findings support the possibility that at
doses above 100 mg daily, aspirin may offer protection
against the development of breast cancer. Many post-
menopausal women require aspirin for the prevention of
cardiovascular events. Increasing the dose from 80 mg
daily to > 100 mg daily in these women may additionally
provide protection against the development of breast can-
cer. This possibility has important public health implica-
tions and requires further investigation.
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